107 related articles for article (PubMed ID: 21083519)
1. Diabetes area participation analysis: a review of companies and targets described in the 2008 - 2010 patent literature.
Carpino PA; Goodwin B
Expert Opin Ther Pat; 2010 Dec; 20(12):1627-51. PubMed ID: 21083519
[TBL] [Abstract][Full Text] [Related]
2. GPR119 agonists for the treatment of type 2 diabetes.
Jones RM; Leonard JN; Buzard DJ; Lehmann J
Expert Opin Ther Pat; 2009 Oct; 19(10):1339-59. PubMed ID: 19780700
[TBL] [Abstract][Full Text] [Related]
3. Latest research and development trends in non-insulin anti-diabetics.
Cheon HG
Arch Pharm Res; 2013 Feb; 36(2):145-53. PubMed ID: 23397318
[TBL] [Abstract][Full Text] [Related]
4. Exploring the pharmacotherapeutic options for treating type 2 diabetes.
Kruger DF
Diabetes Educ; 2008; 34 Suppl 3():60S-65S. PubMed ID: 18525066
[TBL] [Abstract][Full Text] [Related]
5. Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium.
Nathanson D; Nyström T
Mol Cell Endocrinol; 2009 Jan; 297(1-2):112-26. PubMed ID: 19038307
[TBL] [Abstract][Full Text] [Related]
6. Therapy for type 2 diabetes mellitus.
Elson DF; Meredith M
WMJ; 1998 Mar; 97(3):49-54. PubMed ID: 9540451
[TBL] [Abstract][Full Text] [Related]
7. Newly approved and promising antidiabetic agents.
Combettes M; Kargar C
Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
[TBL] [Abstract][Full Text] [Related]
8. Protection of pancreatic beta-cells: is it feasible?
Bonora E
Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
[TBL] [Abstract][Full Text] [Related]
9. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
Neumiller JJ; Wood L; Campbell RK
Pharmacotherapy; 2010 May; 30(5):463-84. PubMed ID: 20411998
[TBL] [Abstract][Full Text] [Related]
11. beta-cell function and anti-diabetic pharmacotherapy.
Del Prato S; Bianchi C; Marchetti P
Diabetes Metab Res Rev; 2007 Oct; 23(7):518-27. PubMed ID: 17883249
[TBL] [Abstract][Full Text] [Related]
12. Consulting on the patient with type 2 diabetes: matching medication to disease mechanism.
Manag Care; 2007 Jun; 16(6 Suppl 5):2-11. PubMed ID: 17703795
[TBL] [Abstract][Full Text] [Related]
13. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
Campbell RK
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
[TBL] [Abstract][Full Text] [Related]
14. The stepwise approach to the management of type 2 diabetes.
Warren RE
Diabetes Res Clin Pract; 2004 Sep; 65 Suppl 1():S3-8. PubMed ID: 15315864
[TBL] [Abstract][Full Text] [Related]
15. The role of glimepiride in the effective management of Type 2 diabetes.
Davis SN
J Diabetes Complications; 2004; 18(6):367-76. PubMed ID: 15531188
[TBL] [Abstract][Full Text] [Related]
16. New therapeutic agents for the treatment of NIDDM.
Kuehnle HF
Exp Clin Endocrinol Diabetes; 1996; 104(2):93-101. PubMed ID: 8740931
[TBL] [Abstract][Full Text] [Related]
17. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes.
Raskin P
Diabetes Metab Res Rev; 2008; 24(1):3-13. PubMed ID: 17968971
[TBL] [Abstract][Full Text] [Related]
18. Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight.
Bonora E
Int J Clin Pract Suppl; 2007 Aug; (154):19-28. PubMed ID: 17593274
[TBL] [Abstract][Full Text] [Related]
19. Statin therapy for the treatment of diabetic dyslipidemia.
Haffner SM
Diabetes Metab Res Rev; 2003; 19(4):280-7. PubMed ID: 12879405
[TBL] [Abstract][Full Text] [Related]
20. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
Campbell RK
Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
